HIMS

24.77

3.90% 0.93

Dopo l'orario di chiusura: 24.54 -0.23 -0.93%

Hims Hers Health Inc (HIMS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché HIMS Giù? Forum Previsione

Precedente Chiudi:

$23.84

Aprire:

$24.07

Volume 24 ore:

42.71M

Relative Volume:

1.48

Capitalizzazione di mercato:

$5.65B

Reddito:

$2.35B

Utile/perdita netta:

$128.37M

Rapporto P/E:

47.44

EPS:

0.5221

Flusso di cassa netto:

$57.42M

1 W Prestazione:

+57.37%

1M Prestazione:

+51.96%

6M Prestazione:

-55.37%

1 anno Prestazione:

-21.46%

Intervallo 1D:

$23.25

$24.82

Intervallo di 1 settimana:

$20.97

$27.54

Portata 52W:

$13.74

$70.43

Hims Hers Health Inc Stock (HIMS) Company Profile

Nome

Hims Hers Health Inc

Settore

Healthcare (1116)

Industria

Drug Manufacturers - Specialty & Generic (83)

Telefono

415-851-0195

Indirizzo

2269 CHESTNUT ST, SAN FRANCISCO

Dipendente

2,442

Cinguettio

Prossima data di guadagno

2025-02-24

Ultimi documenti SEC

HIMS's Discussions on Twitter

Compare HIMS vs TAK, ZTS, HLN, TEVA, UTHR

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
HIMS Hims Hers Health Inc	24.77	5.65B	2.35B	128.37M	57.42M	0.5221
TAK Takeda Pharmaceutical Co Adr	17.77	56.14B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	115.62	48.81B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	10.03	44.67B	14.54B	2.22B	2.58B	0.4879
TEVA Teva Pharmaceutical Industries Ltd Adr	28.57	33.27B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	536.12	23.50B	3.18B	1.33B	1.04B	27.90

Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-03-10	Aggiornamento	BofA Securities	Underperform → Neutral
2026-03-10	Aggiornamento	Citigroup	Sell → Neutral
2026-03-09	Aggiornamento	Needham	Hold → Buy
2026-02-24	Downgrade	BTIG Research	Buy → Neutral
2026-01-12	Iniziato	Evercore ISI	In-line
2025-12-09	Iniziato	Barclays	Overweight
2025-10-21	Iniziato	KeyBanc Capital Markets	Sector Weight
2025-06-23	Downgrade	Needham	Buy → Hold
2025-06-04	Reiterato	Needham	Buy
2025-04-29	Downgrade	TD Cowen	Buy → Hold
2025-02-18	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2025-01-10	Downgrade	Citigroup	Neutral → Sell
2025-01-07	Iniziato	BTIG Research	Buy
2024-12-17	Iniziato	Morgan Stanley	Overweight
2024-11-14	Downgrade	BofA Securities	Buy → Underperform
2024-08-22	Iniziato	Needham	Buy
2024-08-09	Downgrade	Imperial Capital	Outperform → In-line
2024-05-22	Downgrade	Citigroup	Buy → Neutral
2024-04-16	Downgrade	Jefferies	Buy → Hold
2024-04-10	Iniziato	Canaccord Genuity	Buy
2024-02-28	Aggiornamento	Imperial Capital	In-line → Outperform
2024-02-26	Iniziato	Leerink Partners	Market Perform
2023-12-07	Iniziato	Imperial Capital	In-line
2023-07-28	Iniziato	TD Cowen	Outperform
2023-04-11	Iniziato	Robert W. Baird	Neutral
2023-02-09	Aggiornamento	Jefferies	Hold → Buy
2022-11-08	Aggiornamento	BofA Securities	Neutral → Buy
2022-11-08	Aggiornamento	SVB Leerink	Mkt Perform → Outperform
2022-10-17	Downgrade	Piper Sandler	Overweight → Neutral
2022-09-07	Iniziato	Truist	Hold
2022-07-15	Iniziato	SVB Leerink	Underperform
2022-04-14	Iniziato	Guggenheim	Buy
2022-04-01	Ripresa	Credit Suisse	Outperform
2022-03-10	Iniziato	Deutsche Bank	Hold
2021-12-02	Iniziato	Jefferies	Hold
2021-11-11	Aggiornamento	Piper Sandler	Neutral → Overweight
2021-07-06	Iniziato	BofA Securities	Neutral
2021-05-20	Aggiornamento	Credit Suisse	Neutral → Outperform
2021-04-21	Iniziato	Truist	Hold
2021-03-09	Iniziato	Credit Suisse	Neutral
2021-03-02	Aggiornamento	Citigroup	Neutral → Buy
2021-02-17	Iniziato	Citigroup	Neutral
2021-02-12	Iniziato	Piper Sandler	Neutral
2021-02-08	Iniziato	Tigress Financial	Buy

Mostra tutto

Hims Hers Health Inc Borsa (HIMS) Ultime notizie

01:38 AM

Hims & Hers posts best weekly gain after Novo deal - Seeking Alpha

01:38 AM

08:00 AM

OWL, HIMS, TSLA And More: 5 Stocks Investors Couldn't Stop Buzzing About This WeekOracle (NYSE:ORCL) - Benzinga

08:00 AM

02:11 AM

Telehealth Giant Hims Partners with Novo Nordisk After Dropping Legal Battle - Fine Day 102.3

02:11 AM

Mar 13, 2026

Hims And Hers Health Weighs Eucalyptus Deal Against Growth And Valuation Risks - simplywall.st

Mar 13, 2026

Weekly Market Update: Stocks Slide as Financials, Consumer Cyclicals Fall - Morningstar

Mar 13, 2026

Hims & Hers (HIMS) Sees Analyst Optimism Following Novo Resolution - Insider Monkey

Mar 13, 2026

Selling pressure pushes Hims & Hers Health stock lower in today's trading - Traders Union

Mar 13, 2026

Hims & Hers class action alleges semaglutide GLP-1 products falsely advertised - Class Action Lawsuits

Mar 13, 2026

Hims shares set for record week as Novo partnership fuels optimism - Modern Healthcare

Mar 13, 2026

Barclays Raises PT on Hims & Hers Health (HIMS) Stock - Yahoo Finance

Mar 13, 2026

Hims & Hers Health stock price steadies after wild Novo week as focus shifts to margins - TechStock²

Mar 13, 2026

Hims shares set for best week on record after new Novo Nordisk deal - Investing.com

Mar 13, 2026

5 Best Day Trading Stocks to Buy Now - Insider Monkey

Mar 13, 2026

Hims & Hers Stock Jumps After Novo Nordisk Deal. What It Means for Drugmaker - TradingView

Mar 13, 2026

Mar 12, 2026

12 Most Shorted Stocks to Buy in 2026 - Insider Monkey

Mar 12, 2026

Hims & Hers Health and Novo Nordisk end lawsuit over weight loss medications - MSN

Mar 12, 2026

‘They Need Each Other’: Why Hims & Hers and Novo Nordisk Made Up - MedCity News

Mar 12, 2026

Here's Why Hims & Hers Health, Inc. (HIMS) Fell More Than Broader Market - Yahoo Finance

Mar 12, 2026

Hims & Hers stock takes a major hit amid multiple investigations and target cuts - StocksToTrade

Mar 12, 2026

Stock Market Today, March 12: Hims and Hers Health Drops After Rally Sparks Profit Taking - Yahoo Finance

Mar 12, 2026

Hims And Hers Benefits Aims To Deepen Member Loyalty And Engagement - simplywall.st

Mar 12, 2026